Cargando…

Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer

Predictive metabolic biomarkers for the recurrent luminal breast cancer (BC) with hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-negative are lacking. High levels of O-GlcNAcylation (O-GlcNAc) and pyruvate kinase isoenzyme M2 (PKM2) are associated with malign...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Wen-Ling, Tseng, Lin-Lu, Chang, Che-Chang, Chen, Chih-Jung, Cheng, Mei-Ling, Cheng, Hsin-Hung, Wu, Meng-Jen, Chen, Yu-Lun, Chang, Ruei-Ting, Tang, Hsiang-Yu, Hsu, Yong-Chen, Lin, Wen-Jye, Kao, Cheng-Yuan, Hsieh, Wen-Ping, Kung, Hsing-Jien, Wang, Wen-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392504/
https://www.ncbi.nlm.nih.gov/pubmed/34441396
http://dx.doi.org/10.3390/diagnostics11081460
_version_ 1783743519213486080
author Kuo, Wen-Ling
Tseng, Lin-Lu
Chang, Che-Chang
Chen, Chih-Jung
Cheng, Mei-Ling
Cheng, Hsin-Hung
Wu, Meng-Jen
Chen, Yu-Lun
Chang, Ruei-Ting
Tang, Hsiang-Yu
Hsu, Yong-Chen
Lin, Wen-Jye
Kao, Cheng-Yuan
Hsieh, Wen-Ping
Kung, Hsing-Jien
Wang, Wen-Ching
author_facet Kuo, Wen-Ling
Tseng, Lin-Lu
Chang, Che-Chang
Chen, Chih-Jung
Cheng, Mei-Ling
Cheng, Hsin-Hung
Wu, Meng-Jen
Chen, Yu-Lun
Chang, Ruei-Ting
Tang, Hsiang-Yu
Hsu, Yong-Chen
Lin, Wen-Jye
Kao, Cheng-Yuan
Hsieh, Wen-Ping
Kung, Hsing-Jien
Wang, Wen-Ching
author_sort Kuo, Wen-Ling
collection PubMed
description Predictive metabolic biomarkers for the recurrent luminal breast cancer (BC) with hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-negative are lacking. High levels of O-GlcNAcylation (O-GlcNAc) and pyruvate kinase isoenzyme M2 (PKM2) are associated with malignancy in BC; however, the association with the recurrence risk remains unclear. We first conduct survival analysis by using the METABRIC dataset to assess the correlation of PKM2 expression with BC clinical outcomes. Next, patients with HR(+)/HER2- luminal BC were recruited for PKM2/O-GlcNAc testing. Logistic regression and receiver operating characteristic curve analysis were performed to evaluate the 10-year DFS predicted outcome. Survival analysis of the METABRIC dataset revealed that high expression of PKM2 was significantly associated with worse overall survival in luminal BC. The high expression of O-GlcNAc or PKM2 was a significant independent marker for poor 10-year DFS using immunohistochemical analysis. The PKM2 or O-GlcNAc status was a significant predictor of DFS, with the combination of PKM2–O-GlcNAc status and T stage greatly enhancing the predictive outcome potential. In summary, O-GlcNAc, PKM2, and T stage serve as good prognostic discriminators in HR(+)/HER2(−) luminal BC.
format Online
Article
Text
id pubmed-8392504
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83925042021-08-28 Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer Kuo, Wen-Ling Tseng, Lin-Lu Chang, Che-Chang Chen, Chih-Jung Cheng, Mei-Ling Cheng, Hsin-Hung Wu, Meng-Jen Chen, Yu-Lun Chang, Ruei-Ting Tang, Hsiang-Yu Hsu, Yong-Chen Lin, Wen-Jye Kao, Cheng-Yuan Hsieh, Wen-Ping Kung, Hsing-Jien Wang, Wen-Ching Diagnostics (Basel) Article Predictive metabolic biomarkers for the recurrent luminal breast cancer (BC) with hormone receptor (HR)-positive and human epidermal growth factor receptor type 2 (HER2)-negative are lacking. High levels of O-GlcNAcylation (O-GlcNAc) and pyruvate kinase isoenzyme M2 (PKM2) are associated with malignancy in BC; however, the association with the recurrence risk remains unclear. We first conduct survival analysis by using the METABRIC dataset to assess the correlation of PKM2 expression with BC clinical outcomes. Next, patients with HR(+)/HER2- luminal BC were recruited for PKM2/O-GlcNAc testing. Logistic regression and receiver operating characteristic curve analysis were performed to evaluate the 10-year DFS predicted outcome. Survival analysis of the METABRIC dataset revealed that high expression of PKM2 was significantly associated with worse overall survival in luminal BC. The high expression of O-GlcNAc or PKM2 was a significant independent marker for poor 10-year DFS using immunohistochemical analysis. The PKM2 or O-GlcNAc status was a significant predictor of DFS, with the combination of PKM2–O-GlcNAc status and T stage greatly enhancing the predictive outcome potential. In summary, O-GlcNAc, PKM2, and T stage serve as good prognostic discriminators in HR(+)/HER2(−) luminal BC. MDPI 2021-08-12 /pmc/articles/PMC8392504/ /pubmed/34441396 http://dx.doi.org/10.3390/diagnostics11081460 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kuo, Wen-Ling
Tseng, Lin-Lu
Chang, Che-Chang
Chen, Chih-Jung
Cheng, Mei-Ling
Cheng, Hsin-Hung
Wu, Meng-Jen
Chen, Yu-Lun
Chang, Ruei-Ting
Tang, Hsiang-Yu
Hsu, Yong-Chen
Lin, Wen-Jye
Kao, Cheng-Yuan
Hsieh, Wen-Ping
Kung, Hsing-Jien
Wang, Wen-Ching
Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
title Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
title_full Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
title_fullStr Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
title_full_unstemmed Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
title_short Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer
title_sort prognostic significance of o-glcnac and pkm2 in hormone receptor-positive and her2-nonenriched breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392504/
https://www.ncbi.nlm.nih.gov/pubmed/34441396
http://dx.doi.org/10.3390/diagnostics11081460
work_keys_str_mv AT kuowenling prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT tsenglinlu prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT changchechang prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT chenchihjung prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT chengmeiling prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT chenghsinhung prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT wumengjen prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT chenyulun prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT changrueiting prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT tanghsiangyu prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT hsuyongchen prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT linwenjye prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT kaochengyuan prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT hsiehwenping prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT kunghsingjien prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer
AT wangwenching prognosticsignificanceofoglcnacandpkm2inhormonereceptorpositiveandher2nonenrichedbreastcancer